Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence

被引:9
|
作者
Rajesh, V [1 ]
Augustine, Jolsana [1 ]
Divya, R. [1 ]
Cleetus, Melcy [1 ]
机构
[1] Rajagiri Hosp, Dept Pulm Med, Kochi, Kerala, India
关键词
FIXED-DOSE COMBINATION; ADULT PATIENTS; DRY-POWDER; RELATIVE BIOAVAILABILITY; OPEN-LABEL; PROPIONATE; ONSET; BUDESONIDE/FORMOTEROL; SALBUTAMOL; ADOLESCENT;
D O I
10.1155/2020/8631316
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Asthma is the commonest chronic disease affecting airways in humans and has an increasing global disease burden. Inhaled corticosteroids (ICS) are the first-line therapeutic option for asthma, and addition of a long-acting beta 2-agonist (LABA) has been shown to improve asthma control. A combination of the two agents in a single inhaler is beneficial with regard to ease of administration and patient compliance. Various ICS-LABA formulations are available across various countries in the world, one among them being formoterol-fluticasone. Both formoterol and fluticasone have pharmacologic peculiarities which places the combination in a uniquely advantageous position when it comes to asthma therapy. The present review focuses on some of the, hitherto, less explored aspects of this combination inhaler such as real-world efficacy, impact on budget allocation, results of switch-over therapy, and potential to improve adherence to asthma treatment. It also provides practical recommendations on positioning it in real-world asthma management.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Impact of Extrafine Formulation Single-inhaler Triple Therapy on Asthma Control and HRQoL After 1 Year: TriMaximize-A Real-world View in Asthma Therapy from Austria
    Sator, L.
    Voves, R.
    Hoermannstorfer-Fessl, K.
    Keckeis, A.
    Tiefenbacher, F.
    Ambrosch, G.
    Wuertz, M.
    Feizelmeier, H.
    Petrovic, M.
    Nevels, R.
    Pohl, W.
    WIENER KLINISCHE WOCHENSCHRIFT, 2024, 136 : S541 - S541
  • [32] REAL-WORLD ADHERENCE TO SINGLE-INHALER VS MULTIPLE-INHALER TRIPLE THERAPY AMONG PATIENTS WITH COPD IN A COMMERCIALLY INSURED US POPULATION
    Bogart, Michael
    Wu, Benjamin
    Germain, Guillaume
    Laliberte, Francois
    MacKnight, Sean
    Jung, Young
    Duh, Mei
    CHEST, 2020, 158 (04) : 1773A - 1774A
  • [33] Asthma prescribing trends, inhaler adherence and outcomes: a Real-World Data analysis of a multi-ethnic Asian Asthma population
    Toh, Ming Ren
    Ng, Gerald Xuan Zhong
    Goel, Ishita
    Lam, Shao Wei
    Wu, Jun Tian
    Lee, Chun Fan
    Ong, Marcus Eng Hock
    Matchar, David Bruce
    Tan, Ngiap Chuan
    Loo, Chian Min
    Koh, Mariko Siyue
    NPJ PRIMARY CARE RESPIRATORY MEDICINE, 2024, 34 (01)
  • [34] Trioptimize VI: The Use of Extrafine Single Inhaler Triple Therapy Improves Adherence to Treatment in Patients with COPD - Real-World Evidence
    Hoevelmann, R.
    Georges, G.
    Javan, S. Bahari
    Melchior, K.
    Criee, C.
    Gessner, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [35] Budget Impact Analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the Dubai Academic Healthcare Corporation
    Hamouda, Mohamed
    Farghaly, Mohamed
    Al Dallal, Sara
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2023, 15 : 549 - 558
  • [36] Budget Impact Analysis of a Fixed-Dose Combination of Fluticasone Propionate and Formoterol Fumarate (FP/FORM) in a Pressurized Metered-Dose Inhaler (pMDI) for Asthma
    Dunlop, William
    Heron, Louise
    Fox, Georgia
    Greaney, Maire
    ADVANCES IN THERAPY, 2013, 30 (10) : 933 - 944
  • [37] Budget Impact Analysis of a Fixed-Dose Combination of Fluticasone Propionate and Formoterol Fumarate (FP/FORM) in a Pressurized Metered-Dose Inhaler (pMDI) for Asthma
    William Dunlop
    Louise Heron
    Georgia Fox
    Maire Greaney
    Advances in Therapy, 2013, 30 : 933 - 944
  • [38] Real-World Outcomes on Spacer used with Extrafine Single-Inhaler Triple Therapy in Asthma Patients-TriMaximize Study
    Trinkmann, F.
    Nachtigall, D.
    Bogoevska, V
    Akyildiz, B.
    Borucki, T.
    Grickschat, V
    Gessner, C.
    PNEUMOLOGIE, 2024, 78 : S4 - S4
  • [39] MAINTENANCE AND RELIEVER BUDESONIDE/FORMOTEROL THERAPY HAS A FAVOURABLE RISK/BENEFIT PROFILE IN REAL-WORLD ASTHMA
    Beasley, R.
    Patel, M.
    Pilcher, J.
    Weatherall, M.
    Black, P.
    RESPIROLOGY, 2013, 18 : 13 - 13
  • [40] Randomized controlled trial of adherence with single or combination inhaled corticosteroid/long-acting β-agonist inhaler therapy in asthma
    Perrin, Kyle
    Williams, Mathew
    Wijesinghe, Meme
    James, Kate
    Weatherall, Mark
    Beasley, Richard
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 126 (03) : 505 - 510